1. Search Result
Search Result
Results for "

C57BL/6 Sepsis

" in MedChemExpress (MCE) Product Catalog:

90

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

17

Peptides

4

Inhibitory Antibodies

12

Natural
Products

1

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117427

    Others Metabolic Disease
    D5D-IN-326 is a selective, orally active delta-5 desaturase (D5D) inhibitor, with IC50s of 72 and 22 nM for rat and human D5D in enzymic and cell-based assays, respectively, has no effect on D6D or D9D activity. D5D-IN-326 reduces insulin resistance and decreases body weight in diet-induced obese C57BL/6J mice .
    D5D-IN-326
  • HY-160025

    Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO antagonist-1 (compound 163) is an antagonist of IDO . IDO antagonist-1 inhibits pancreatic adenocarcinoma cells growth in C57BL/6 mice .
    IDO antagonist-1
  • HY-128435

    Others Metabolic Disease
    2,4'-Dihydroxybenzophenone ((Z)-SU4312) exhibited estrogenic activities. 2,4'-Dihydroxybenzophenone has oral bioactivity that can effectively protect C57BL/6J mice from Acetaminophen (HY-66005, APAP)-induced hepatotoxicity .
    2,4'-Dihydroxybenzophenone-1
  • HY-157429

    5-HT Receptor Neurological Disease
    25N-N1-Nap (compound 16) is a β-arrestin-biased 5-HT2A agonist. 25N-N1-Nap antagonizes phencyclidine induced hyperactivity in Male C57BL/6?J mice .
    25N-N1-Nap
  • HY-144743

    Phosphodiesterase (PDE) Others
    ATX inhibitor 12 (compound 20) is an orally active and potent ATX (autotaxin) inhibitor, with an IC50 of 1.72 nM. ATX inhibitor 12 effectively alleviates lung structural damage with fewer fibrotic lesions at an oral dose of 60 mg/kg in C57Bl/6J mice. ATX inhibitor 12 can be uesd for idiopathic pulmonary fibrosis (IPF) research .
    ATX inhibitor 12
  • HY-146292

    Epigenetic Reader Domain Infection
    BET-IN-8 (Compound 27) is a potent inhibitor of BET with a Ki and Kd of 0.83 and 0.571 μM, respectively. BET-IN-8 ameliorates LPS-induced sepsis in vivo. BET-IN-8 has the potential for the research of sepsis .
    BET-IN-8
  • HY-P99753

    BAYX1351

    TNF Receptor Infection
    Nerelimomab (BAYX1351) is an anti-TNF-α antibody. Nerelimomab can be used for research of sepsis .
    Nerelimomab
  • HY-162120

    Epoxide Hydrolase Infection
    FZQ-21 (Compound 70P) is a soluble epoxide hydrolase (sEH) inhibitor, with an IC50 of 4 nM. FZQ-21 exhibits equal IC50 (1.5 nM) on inhibiting human sEH as EC5026 (HY-135653) (1.7 nM). FZQ-21 can be used for research of sepsis .
    FZQ-21
  • HY-146291

    Epigenetic Reader Domain Infection
    BET-IN-7 (Compound 1) is a potent inhibitor of BET with a Ki and Kd of 12.27 and 89.3 μM, respectively. BET-IN-7 has the potential for the research of sepsis .
    BET-IN-7
  • HY-162260

    MNK Cancer
    MNK-IN-4 (compound D25) is a potent and selective MNK inhibitor for the treatment of sepsis-related acute splenic injury .
    MNK-IN-4
  • HY-115977

    Aldose Reductase Inflammation/Immunology
    Aldose reductase-IN-3 (Compound 5) is a potent and moderately selective inhibitor of aldose reductase (AR) with an IC50 of 3.99 μM. Aldose reductase has recently emerged as a molecular target that is involved in various inflammatory diseases, including sepsis. Aldose reductase-IN-3 has the potential for the research of sepsis .
    Aldose reductase-IN-3
  • HY-151970

    STING Inflammation/Immunology
    STING-IN-4 (Compound 1) is a STING inhibitor that inhibits STING expression and hence reducing activation of STING and nuclear factor-κB (NF-κB) signaling. STING-IN-4 shows anti-inflammatory activity and can be used for the research of sepsis .
    STING-IN-4
  • HY-P5949

    Bacterial Infection
    AMPR-22 is an antimicrobial peptide. AMPR-22 can bind to the bacterial membrane and induces membrane permeabilization. AMPR-22 is effective against murine model of sepsis induced by MDR strains
    AMPR-22
  • HY-103017
    JH-X-119-01 hydrochloride
    3 Publications Verification

    IRAK Infection
    JH-X-119-01 hydrochloride is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 hydrochloride ameliorates LPS-induced sepsis in mice .
    JH-X-119-01 hydrochloride
  • HY-P10208A

    Toll-like Receptor (TLR) Infection Inflammation/Immunology
    RKH acetate exerts protective effects against sepsis-induced death and organ damage. RKH acetate can directly bind to Toll-like receptor 4 (TLR4) and block TLR4 signal transduction in immune cells .
    RKH acetate
  • HY-P2280

    Dynamin Neurological Disease Inflammation/Immunology
    TAT-P110, a peptide inhibitor of Drp1-Fis1 interaction, reduces pathology in numerous models of neurodegeneration, ischemia, and sepsis without blocking the physiological functions of Drp1 .
    TAT-P110
  • HY-P10208

    Toll-like Receptor (TLR) Infection
    PKH is a TLR4 antagonist. PKH is a novel tripeptide and can be isolated from Akkermansia muciniphila. RKH reduces sepsis-induced inflammatory cell activation and proinflammatory factor overproduction .
    RKH
  • HY-161059

    RIP kinase Infection
    ZB-R-55 is an orally active RIPK1 inhibitor. ZB-R-55 can be used for sepsis study .
    ZB-R-55
  • HY-P99425

    MAK 195F

    TNF Receptor Infection Inflammation/Immunology
    Afelimomab (MAK 195F) is an anti-tumor necrosis factor F(ab')2 monoclonal antibody fragment. Afelimomab can be used for the research of sepsis .
    Afelimomab
  • HY-152034

    STING Inflammation/Immunology
    STING-IN-5 is a potent STING inhibitor, inhibiting LPS-induced NO synthesis in macrophages with an IC50 value of 1.15 μM. STING-IN-5 inhibits the inflammatory response. STING-IN-5 can be used to research anti-inflammatory diseases and sepsis .
    STING-IN-5
  • HY-12124

    NO Synthase Cardiovascular Disease
    BBS-4 is a potent and selective inducible nitric oxide synthase (NOS2) dimerization inhibitor, with an IC50 of 0.49 nM. BBS-4 can protect mice from the cardiovascular dysfunction of sepsis .
    BBS-4
  • HY-145996

    Bacterial Infection
    STC314 is a small polyanion that interact electrostatically with histones. STC314 blocks disruption of lipid-bilayers by histones that inhibits the cytotoxic, platelet-activating and erythrocyte-damaging effects of histones. STC314 has anti-infective effects and can be uesd for sepsis research .
    STC314
  • HY-103639

    Toll-like Receptor (TLR) Inflammation/Immunology
    M62812 (free base) is a toll-like receptor 4 (TLR4) signal transduction inhibitor. M62812 can suppress endothelial cell and leukocyte activation and prevents lethal septic shock in mice. M62812 can be used for the research of sepsis .
    M62812 free base
  • HY-P3031

    MAPK1

    p38 MAPK NF-κB Inflammation/Immunology
    Mitogen-activated protein kinase 1 (MAPK1) can activate the downstream p38/NF-κB pathway. Mitogen-activated protein kinase 1 can regulate cellular processes in various sepsis-associated diseases. MAPK-catalyzed phosphorylation of substrate proteins functions as a switch to turn on or off the activity of the substrate protein .
    Mitogen-activated protein kinase 1
  • HY-103639A

    Toll-like Receptor (TLR) Infection
    M62812 is a toll-like receptor 4 (TLR4) signaling inhibitor. M62812 inhibits endothelial and leukocyte activation and prevents lethal septic shock in mice. M62812 can reduces LPS-induced coagulation and inflammatory responses. M62812 can be used for the research of sepsis .
    M62812
  • HY-156367

    RIP kinase Inflammation/Immunology
    RIPK1-IN-16 is an orally active and potent inhibitor of RIPK1. RIPK1-IN-16 inhibits excessive inflammation by blocking RIPK1-mediated necroptosis in vivo. RIPK1-IN-16 protects mouse from TNF-induced systemic inflammatory response syndrome and sepsis .
    RIPK1-IN-16
  • HY-P99520

    CaCP-29, IFX-1

    Complement System SARS-CoV Infection Inflammation/Immunology
    Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .
    Vilobelimab
  • HY-161520

    Glucocorticoid Receptor NF-κB Inflammation/Immunology
    Glucocorticoid receptor/NF-κB modulator-1 (Compound 20) is a derivative of ocotillol. Glucocorticoid receptor/NF-κB modulator-1 suppresses the degradation of glucocorticoid receptor (GR) mRNA and GR protein, inhibits the activation of NF-κB signaling pathway. Glucocorticoid receptor/NF-κB modulator-1 downregulates levels of NO, interleukin-6 and tumor necrosis factor-alpha (TNF-α). Glucocorticoid receptor/NF-κB modulator-1 ameliorates sepsis in mouse model .
    Glucocorticoid receptor/NF-κB modulator-1
  • HY-161471

    Ser/Thr Protease Inflammation/Immunology
    DCLK1-IN-5 (Compound a24) is a DCLK1 inhibitor (IC50: 179.7 nM). DCLK1-IN-5 inhibits lipopolysaccharide (HY-D1056)-induced inflammation via inhibiting DCLK1-mediated IKKβ phosphorylation. DCLK1-IN-5 protects mice against inflammation-induced lung injury and sepsis .
    DCLK1-IN-5
  • HY-102065

    Prostaglandin Receptor Others
    SC-19220 is a competitive prostaglandinn E2 receptor antagonist. SC-19220 increases the bladder capacity and reduced the voiding efficiency of micturition (elicited by slow transvesical filling) of urethane-anesthetized rats. SC-19220 can restores the balance in bone marrow granulocyte and monocyte production after burn sepsis .
    SC-19220
  • HY-P2682

    MMP Metabolic Disease
    MMP-8/MMP-26 Fluorogenic substrate (DNP-Pro-Leu-Ala-Tyr-Trp-Ala-Arg) is a matrix metalloproteinase-8 (MMP-8) fluorogenic substrate. MMP-8/MMP-26 Fluorogenic substrate can be used for the research of atherosclerosis, pulmonary fibrosis, and sepsis .
    MMP-8/MMP-26 Fluorogenic substrate
  • HY-149485

    JNK Inflammation/Immunology
    JNK2-IN-1 (Compound J27) is a JNK2 inhibitor (Kds: 79.2 μM). JNK2-IN-1 has anti-inflammatory activity. JNK2-IN-1 decreases the release of TNF-α and IL-6 through inhibiting the activation of NF-κB/MAPK pathway. JNK2-IN-1 alleviates the symptoms of LPS-induced acute lung injury (ALI) and sepsis .
    JNK2-IN-1
  • HY-P2458

    Bacterial Infection
    CAP18 (rabbit) is a 37 amino acids antimicrobial peptide originally isolated from rabbit granulocytes. CAP18 (rabbit) has broad antimicrobial activity against both Gram-positive (IC50, 130-200 nM) and Gram-negative (IC50, 20-100 nM) bacteria. CAP18 (rabbit) has the potential for bacterial sepsis research .
    CAP18 (rabbit)
  • HY-P3612

    CXCR Inflammation/Immunology
    CTCE-0214 is a chemokine CXC receptor 4 (CXCR4) agonist, SDF-1α (stromal cell-derived factor-1α) peptide analog. CTCE-0214 shows anti-inflammatory activity, and can be used in inflammation sepsis and systemic inflammatory syndromes research .
    CTCE-0214
  • HY-163478

    NF-κB Inflammation/Immunology
    TNIK-IN-9 (Compound 54) is a selective and potent NIK inhibitor, with an IC50 of 1.27 nM. TNIK-IN-9 can inhibit pro-inflammatory cytokines and nitric oxide production. TNIK-IN-9 exhibits significant anti-inflammatory effects, improved mortality, and hepatoprotective effects in sepsis models .
    TNIK-IN-9
  • HY-100574A
    Cl-amidine hydrochloride
    Maximum Cited Publications
    10 Publications Verification

    Protein Arginine Deiminase Apoptosis MicroRNA Inflammation/Immunology Cancer
    Cl-amidine hydrochloride is an orally active peptidylarginine deminase (PAD) inhibitor, with IC50 values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine hydrochloride induces apoptosis in cancer cells. Cl-amidine hydrochloride induces microRNA (miR)-16 (miRNA-16, microRNA-16) expression and causes cell cycle arrest. Cl-Amidine hydrochloride prevents histone 3 citrullination and neutrophil extracellular trap formation, and improves survival in a murine sepsis model .
    Cl-amidine hydrochloride
  • HY-100574

    Protein Arginine Deiminase Apoptosis MicroRNA Inflammation/Immunology Cancer
    Cl-amidine is an orally active peptidylarginine deminase (PAD) inhibitor, with IC50 values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine induces apoptosis in cancer cells. Cl-amidine induces microRNA (miR)-16 (miRNA-16, microRNA-16) expression and causes cell cycle arrest. Cl-Amidine prevents histone 3 citrullination and neutrophil extracellular trap formation, and improves survival in a murine sepsis model .
    Cl-amidine
  • HY-N6018

    Caspase TNF Receptor SOD Reactive Oxygen Species Inflammation/Immunology Cancer
    Beta-Eudesmol has anticancer and anti-inflammatory activities. Beta-Eudesmol can induce apoptosis. Beta-Eudesmol is a neostigmine antagonist. Beta-Eudesmol can antagonize neostigmine-induced neuromuscular failure. Beta-Eudesmol can be used in the study of sepsis diseases. Beta-Eudesmol is a sesquiterpene-like compound that can be extracted from the rhizome of Atractylodes lancea .
    Beta-Eudesmol
  • HY-161072

    NOD-like Receptor (NLR) Inflammation/Immunology
    CSC-6 is a NLRP3 inhibitor. CSC-6 can significantly inhibit IL-1β secreted by PMATHP-1 cells with an IC50 value of 2.3 μM. CSC-6 specifically binds NLRP3 and inhibits NLRP3 activation by blocking ASC oligomerization during NLRP3 assembly. CSC-6 effectively reduces the symptoms of NLRP3 overactivation-mediated sepsis and gout in mouse models .
    CSC-6
  • HY-100574B

    Protein Arginine Deiminase Apoptosis MicroRNA Inflammation/Immunology Cancer
    Cl-amidine TFA is an orally active peptidylarginine deminase (PAD) inhibitor, with IC50 values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine TFA induces apoptosis in cancer cells. Cl-amidine TFA induces microRNA (miR)-16 (miRNA-16, microRNA-16) expression and causes cell cycle arrest. Cl-Amidine TFA prevents histone 3 citrullination and neutrophil extracellular trap formation, and improves survival in a murine sepsis model .
    Cl-amidine TFA
  • HY-145307

    Bacterial Infection Inflammation/Immunology
    DATPT is a 12WLVSKF17 peptide-mimetic molecule. DATPT blocks the SNX9-p47phox interaction in the endosome and suppresses reactive oxygen species and inflammatory cytokine production. DATPT with anti-inflammatory and antibacterial functions has the potential for the research of sepsis .
    DATPT
  • HY-126154

    Toll-like Receptor (TLR) Inflammation/Immunology
    L48H37 is an analog of Curcumin (HY-N0005) with improved chemical stability. L48H37 is a potent and specific myeloid differentiation protein 2 (MD2) inhibitor and inhibits the interaction and signaling transduction of LPS-TLR4/MD2. L48H37 is used for the research of sepsis or lung injury treatment .
    L48H37
  • HY-146066

    nAChR JAK STAT NO Synthase Inflammation/Immunology
    α7 nAchR-JAK2-STAT3 agonist 1 is a potent α7 nAchR-JAK2-STAT3 agonist, with an IC50 value of 0.32 μM for nitric oxide (NO). α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages. α7 nAchR-JAK2-STAT3 agonist 1 can inhibit LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 can be used for researching sepsis .
    α7 nAchR-JAK2-STAT3 agonist 1
  • HY-P10368

    Dynamin Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
    P110, a peptide inhibitor of Drp1-Fis1 interaction, reduces pathology in numerous models of neurodegeneration, ischemia, and sepsis without blocking the physiological functions of Drp1 .
    P110
  • HY-156519

    NF-κB Inflammation/Immunology
    ALPK1-IN-3 is an inhibitor of ALPK1 extracted from patent WO2022063153A1 compound T007. ALPK1-IN-3 inhibits kidney proinflammatory gene expression and improves the survival rate of the animals in sepsis induced acute kidney injury animal model . ALPK1-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    ALPK1-IN-3
  • HY-143456

    Others Inflammation/Immunology
    Anti-inflammatory agent 18 (compound 3b) shows NO inhibitory activity, with an IC50 of 15.94 μM. Anti-inflammatory agent 18 inhibits HMGB1-induced later inflammation. Anti-inflammatory agent 18 can be used for the research of later inflammation diseases such as coronavirus diseases (COVID-19) and sepsis, etc .
    Anti-inflammatory agent 18
  • HY-143457

    Others Inflammation/Immunology
    Anti-inflammatory agent 19 (compound 2b) shows NO inhibitory activity, with an IC50 of 36.00 μM. Anti-inflammatory agent 19 inhibits HMGB1-induced later inflammation. Anti-inflammatory agent 19 can be used for the research of later inflammation diseases such as coronavirus diseases (COVID-19) and sepsis, etc .
    Anti-inflammatory agent 19
  • HY-B1924
    Norvancomycin hydrochloride
    1 Publications Verification

    Desmethyl-vancomycin hydrochloride

    Bacterial Antibiotic Infection
    Norvancomycin hydrochloride is suitable for endocarditis, osteomyelitis, pneumonia, sepsis or soft tissue infections caused by Staphylococcus aureus (including methicillin-resistant strains and multi-drug-resistant strains).
    Norvancomycin hydrochloride
  • HY-P99309

    BSYX-A 110; Anti-S. Epidermidis LTA Recombinant Antibody

    Bacterial Infection
    Pagibaximab is a chimeric IgG1 antibody recognizing the surface component lipoteichoic acid of S. aureus and S. epidermidis. Pagibaximab can be used to prevent staphylococcal sepsis .
    Pagibaximab
  • HY-144220

    NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3/AIM2-IN-1 is a thermal sepsis inhibitor with an < b > IC < sub > 50 < / sub > < / b > value of 3.136 ± 0.7667 μ M.
    NLRP3/AIM2-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: